Overview
RAPP market data
Price History
RAPP price chart · 1M
- O
- 51.96
- H
- 52.93
- L
- 50.71
- C
- 50.89
- Vol
- 23,114.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $51.96
- Previous Close
- $52.55
- Day High
- $52.93
- Day Low
- $50.71
- 52 Week High
- $52.93
- 52 Week Low
- $32.41
- 7 Day Return
- +6.20%
- 30 Day Return
- +21.25%
- 90 Day Return
- +28.87%
- 1 Year Return
- +54.21%
- Daily Notional Volume
- $1.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.86 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.47 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.11 – $51.38 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.3B · P/B 2.98.
Company News
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price TargetBenzinga · Aug 19, 2026, 10:25 AM
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66Benzinga · Aug 12, 2026, 4:58 PM
Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) EstimateBenzinga · Aug 5, 2026, 11:24 AM
8-K filing — Rapport Therapeutics, Inc. (RAPP)SEC EDGAR · Aug 5, 2026, 11:17 AM
Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $52Benzinga · Jun 24, 2026, 6:45 PM